NUVB: Nuvation Bio Inc. insider trading, 5% holders and institutional ownership
From public SEC filings: open-market insider purchases and sales (Form 4, last 180 days), holders of 5% or more (Schedules 13D and 13G) and institutional ownership (Form 13F). Insider and 5% data delayed 48 hours.
Insider trading
0 open-market buys totaling - and 0 sales totaling - in the last 180 days.
Institutional ownership (Q2 2026)
244 institutions reported holding $1.28B of Nuvation Bio Inc. on Form 13F (233 the quarter before). 39 opened a new position and 26 sold out. Shares held by institutions: +5%.
| Largest holders | Shares | Value |
|---|---|---|
| FMR LLC | 52,230,295 | $296.67M |
| BlackRock, Inc. | 27,630,837 | $156.94M |
| Decheng Capital LLC | 25,954,439 | $147.42M |
| VANGUARD CAPITAL MANAGEMENT LLC | 11,919,514 | $67.70M |
| Omega Fund Management, LLC | 8,081,089 | $45.90M |
| Laurion Capital Management LP | 7,820,013 | $44.42M |
| STATE STREET CORP | 7,370,794 | $41.87M |
| GEODE CAPITAL MANAGEMENT, LLC | 6,244,805 | $35.48M |
| AMERICAN CENTURY COMPANIES INC | 4,499,643 | $25.56M |
| BANK OF AMERICA CORP /DE/ | 3,529,748 | $20.05M |
Clinical trial readouts
1 Phase 2 or 3 trials by Nuvation Bio Inc. with a primary completion date in the last 90 days or the next 12 months and no results posted yet, from ClinicalTrials.gov. (est.) = company estimate.
| Primary completion | Drug | Condition | Phase | Patients | Status | Trial |
|---|---|---|---|---|---|---|
| 2027-03 (est.) | NUV-1511 | Advanced Solid Tumor | Phase 1/2 | 466 | Enrollment complete | NCT06334432 |
Get new insider and activist filings the morning after: daily alerts. Not investment advice.